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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
We aim to assess the clinical effectiveness and side-effect profile of uterotonic drugs to prevent PPH, and to generate a clinically useful
ranking of available uterotonics according to their effectiveness and side-effects. We will explore the effects according to various key
prognostic and treatment factors. The population of interest is women following a vaginal birth or a caesarean section in the hospital or
the community setting. All uterotonic drugs considered by theWHO are eligible and the outcomes include blood loss-related outcomes
and side-effects.
B A C K G R O U N D
Description of the condition
An estimated 289,000 women died during childbirth in 2013
(WHO 2014). Almost all (99%) deaths occurred in developing
countrieswherewomengive birth in communitieswith nomedical
support. Postpartum haemorrhage (PPH) is one of the leading
causes of maternal death worldwide, accounting for up to a third
of all deaths (Say 2014). Even when death is avoided, the need for
blood transfusion, hysterectomy and the risks for morbidity are
high, even in developed countries (Penney 2007).
The third stage of labour, defined as the period of time from birth
until the delivery of the placenta, and the immediate postpartum
period are the most hazardous periods of childbirth due to the risk
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of PPH. The World Health Organization (WHO) defines PPH
when blood loss after birth exceeds 500 mL in the first 24 hours
(WHO 2012). Even though healthy women can easily cope with
this amount of blood loss, for women of low-income countries
who may be malnourished and anaemic it can cause considerable
morbidity and mortality. The primary cause of PPH as defined by
WHO is uterine atony, which accounts for 75% of cases (Weekes
1956). Even though risk factors for adverse maternal outcomes
from severe haemorrhage have been identified (Souza 2013), of-
ten PPH is unpredictable as it occurs in the absence of identifi-
able clinical or historical risk factors (Combs 1991). Therefore,
effective prevention of PPH is advocated for all women during
childbirth (WHO 2012). The administration of uterotonic drugs
routinely in the third stage of labour is a key intervention that pre-
vents PPH, although there is uncertainty about which drug may
be the most effective.
Description of the intervention
The administration of uterotonic drugs to prevent PPH is part
of the active management of the third stage of labour, which can
prevent two out of three events of PPH (Begley 2011). The active
management of the third stage of labour refers to the adminis-
tration of a uterotonic drug, early cord clamping, and controlled
cord traction until delivery of the placenta. The WHO guideline
development group recently revisited the evidence underpinning
each component of the active management of third stage of labour
and considered the use of uterotonics as the main intervention
within this package (WHO 2012). Uterotonics are also essential
for the treatment of PPH, but this is not considered in this review.
How the intervention might work
Many different uterotonic drugs have been used for preventing
PPH. These include oxytocin, ergometrine, misoprostol, carbe-
tocin, and others, alone or in combination.
Oxytocin
Oxytocin (Syntocinon®) is themost widely used uterotonic drug.
At low doses, it produces rhythmic uterine contractions that are
indistinguishable in frequency, force and duration from those ob-
served during spontaneous labour, but at higher dosages, it causes
sustained tetanic uterine contractions (MEDICINES.ORG.UK).
It has a short half-life, approximately three to five minutes, and
can be used as an infusion to maintain uterine contraction.
When used intramuscularly, the latent phase lasts two to five
minutes, but the uterine activity can last two to three hours
(MEDICINES.ORG.UK). However, oxytocin cannot be used
orally. It is unstable in ambient temperatures and it requires a
cold chain through storage and transport. It should also not be
given intravenously as a large bolus, because it can cause severe
hypotension (Thomas 2007). Because of its anti-diuretic effect,
water intoxication can occur with prolonged infusion of oxytocin
(MEDICINES.ORG.UK). Oxytocin has a favourable side-effect
profile and it is not significantly worse than placebo for common
side-effects such as nausea and vomiting, but the evidence is scarce
(Westhoff 2013).
Ergometrine
Ergometrine and methylergometrine are ergot alkaloids that in-
crease the uterine muscle tone by causing continuous tetanic con-
tractions. It has a latent phase of two to fiveminutes after intramus-
cular injection and the plasma half-life is 30 to 120 minutes (de
Groot 1998). However, ergometrine and methylergometrine are
unstable in heat with an unpredictable bioavailability, which pre-
cludes oral use (de Groot 1996). They are vasoconstrictive and in-
crease the risk of hypertension postpartum (Liabsuetrakul 2007).
Other side-effects with ergot alkaloids are pain after birth, nausea
and vomiting (Liabsuetrakul 2007).
Misoprostol
Misoprostol is a prostaglandin E1 analogue, which is licensed for
the prevention and treatment of gastric ulcers. It is well known for
its off-label use as a uterotonic agent (Tuncalp 2012). It is water-
soluble and heat stable (Davies 2001). It is absorbed after nine
to 15 minutes after sublingual, oral, vaginal, and rectal use. The
half-life is about 20 to 40 minutes. Oral and sublingual routes
have the advantage of rapid onset of action, while the vaginal and
rectal routes result in prolonged activity and greater bioavailability
(Schaff 2005). However, it is associated with side-effects such as
diarrhoea, abdominal pain, nausea and vomiting, shivering and
pyrexia (Tuncalp 2012). Other prostaglandins are available in in-
jectable form such as PGF2alpha analogues (carboprost). How-
ever, PGF2alpha analogues are only used to treat PPH when it is
not controlled by other methods due their cost and availability.
Carbetocin
Carbetocin is a newer long-acting synthetic analogue of oxytocin
with agonist properties. After intravenous injection, it produces
tetanic uterine contractions within two minutes, lasting for ap-
proximately six minutes followed by rhythmic contractions for 60
minutes (Hunter 1992). When carbetocin is administered by an
intramuscular injection the tetanic contractions last for approxi-
mately 11 minutes and the rhythmic contractions for 120 min-
utes (Hunter 1992). Carbetocin is heat stable and the side-effect
profile appears to be similar to oxytocin (Su 2012).
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Combination drugs
The use of combinations of uterotonic drugs is also popular and
themost commonly used preparation is oxytocin plus ergometrine
(syntometrine®). This combination is associated with a statisti-
cally significant reduction of PPH above 500 mL when compared
with oxytocin alone, attributable to the additive ergometrine effect
(odds ratio (OR) 0.82, 95% confidence interval (CI) 0.71, 0.95)
(McDonald 2004). Another combination is oxytocin plus miso-
prostol that is also found to be associated with a small reduction
in PPH above 500 mL (risk ratio (RR) 0.71, 95% CI 0.53, 0.95)
(Tuncalp 2012). However, both these combinations are associated
with significant side-effects and despite the small difference in
PPH, there is no difference found for severe PPH when compared
to oxytocin. This has led the WHO to recommend oxytocin over
these combinations (WHO 2012).
The WHO recommends that all women giving birth should be
offered uterotonics during the third stage of labour for the pre-
vention of PPH; oxytocin (intramuscular/intravenous, 10 inter-
national units (IU) is the uterotonic drug of choice (WHO 2012).
Other injectable uterotonics and misoprostol are recommended as
alternatives for the prevention of PPH in settings where oxytocin
is not available. Carbetocin is found to reduce the need for addi-
tional uterotonics (RR 0.62; 95% CI 0.44, 0.88), but it is more
expensive and not better than oxytocin for preventing PPH above
1000 mL (WHO 2012).
Why it is important to do this review
Several Cochrane reviews have compared individual uterotonic
drugs with other uterotonic drugs or with placebo or no treatment
(Begley 2011; Liabsuetrakul 2007; McDonald 2004; Su 2012;
Tuncalp 2012; Westhoff 2013). A standard pairwise meta-analy-
sis however, can only compare two drugs that have been directly
compared in head-to-head trials (direct evidence). In the absence
of a single high-quality, randomised controlled trial comparing all
available uterotonic drugs, uncertainty remains about which is the
most effective drug for preventing PPH. A network meta-analysis
allows evidence synthesis when there is a range of interventions
available, in order to make comparisons across all pairs of inter-
ventions using direct and indirect trial data in a coherent manner.
Indirect evidence is obtained by inferring the relative effective-
ness of two competing treatments through a common comparator
(Lumley 2002). Thus a network meta-analysis produces estimates
of relative effects for each treatment compared with every other
in the network, even though some pairs may not have been di-
rectly compared, and has the potential to reduce the uncertainty
in effect estimates (Caldwell 2005). It also allows the calculation
of the probability that each treatment is the best for any given
outcome and can be used to identify gaps in the evidence base,
thus informing future research agendas.
O B J E C T I V E S
We aim to assess the clinical effectiveness and side-effect profile of
uterotonic drugs to prevent PPH, and to generate a clinically useful
ranking of available uterotonics according to their effectiveness
and side-effects. We will explore the effects according to various
key prognostic and treatment factors. The population of interest
is women following a vaginal birth or a caesarean section in the
hospital or the community setting. All uterotonic drugs considered
by the WHO are eligible and the outcomes include blood loss-
related outcomes and side-effects.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled comparisons or cluster trials of effec-
tiveness or side-effects of uterotonic drugs for preventing PPHwill
be included. Quasi-randomised trials and cross-over trials will be
excluded.
Types of participants
The review will consider studies including pregnant women fol-
lowing a vaginal birth or caesarean section conducted in both hos-
pital and community settings.
Types of interventions
We will consider trials of uterotonics described by WHO (WHO
2012) (oxytocin, ergometrine, misoprostol, carbetocin, or combi-
nations of uterotonics) administered prophylactically by health-
care professionals for preventing PPH via any systemic route (sub-
lingual, subcutaneous, intramuscular, rectal, oral, intravenous bo-
lus and/or infusion) compared with another uterotonic or with
placebo or no treatment. If we identify in the included studies
interventions that we are not aware of, we will consider them as
eligible and include them in the network after assessing their com-
parability with those named above. We will include trials in which
non-pharmacologic co-interventions such as controlled cord trac-
tion, cord clamping, or uterine massage was performed as a ran-
domised intervention in all arms of the trial. We will stratify all
drugs according to mode of birth, prior risk of PPH, healthcare
setting, specific dosage, regimen and route, to detect inequalities
in subgroups that could affect comparative effectiveness.
Figure 1 shows the overall network of eligible comparisons in the
review at a drug level.
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Figure 1. Overall network of eligible comparisons at a class level.
Multi-arm trials that compare different dosages, regimens or routes
of one uterotonic drug, but also compare those versus another
uterotonic drug, will be included. Intervention arms of different
dosages, regimens or routes of the same uterotonic drug will be
merged together for the global analysis of all outcomes and treated
as separate independent comparisons only for the relevant sub-
group analysis according to dosage, regimen and route of drug
administration, while taking into account the correlation between
the comparisons. We will exclude trials comparing exclusively dif-
ferent dosages, regimens or routes of administration of the same
uterotonic drug. The review will be restricted to studies evaluating
uterotonic drugs administered systemically at the birth of the baby
for preventing PPH. Studies considering non-uterotonic drugs,
uterotonic drugs administered locally (for example, via intraum-
bilical or intrauterine routes) or at a later stage of delivery (for
example, for the treatment of PPH or for retained placenta) will
be excluded.
We assume that any patient that meets the inclusion criteria is,
in principle, equally likely to be randomised to any of the eligible
uterotonic drugs.
Types of outcome measures
We will estimate the relative effects and ranking of the competing
interventions according to the following outcomes.
Primary outcomes
The primary outcomes of the review are:
1. primary PPH above or equal to 500 mL; and
2. primary PPH above or equal to 1000 mL.
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Secondary outcomes
The secondary outcomes of the review are:
1. maternal death;
2. maternal deaths or severe morbidity events adapted from
WHO “near miss” criteria (WHO 2011) to include major
surgery (laparotomy, uterine artery ligation, internal iliac artery
ligation, B-Lynch suture, hysterectomy, extensive vaginal repair,
admission to the intensive care unit, or vital organ failure
(temporary or permanent);
3. additional uterotonics requirement;
4. transfusion requirement;
5. manual removal of the placenta;
6. mean volumes of blood loss (mL);
7. mean durations of the third stage of labour (minutes);
8. change in haemoglobin measurements before and after
birth (g/L);
9. clinical signs of blood loss;
10. neonatal unit admission requirement;
11. breastfeeding at discharge; and
12. side-effects such as nausea, vomiting, hypertension,
headache, tachycardia, hypotension, abdominal pain, fever and
shivering in the first 24 hours postpartum.
Search methods for identification of studies
The following methods section of this protocol is based on a stan-
dard template used by the Cochrane Pregnancy and Childbirth
Group.
Electronic searches
We will contact the Trials Search Co-ordinator to search the
Cochrane Pregnancy and Childbirth Group’s Trials Register.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL, MEDLINE, Em-
base and CINAHL, the list of handsearched journals and confer-
ence proceedings, and the list of journals reviewed via the current
awareness service can be found in the ‘Specialized Register’ section
within the editorial information about the Cochrane Pregnancy
and Childbirth Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
In addition, we will search ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform (ICTRP) for unpub-
lished trial reports. The search terms we plan to use are given in
Appendix 1 and any changes to this will be documented fully in
the review.
Searching other resources
Wewill retrieve additional relevant references cited in papers iden-
tified through the above search strategy. We will search for the full
texts of studies identified as abstracts.
We will seek information from primary authors to investigate
whether these studies meet eligibility criteria, and to obtain out-
come and study data. Trials that compare at least two of the drugs
are eligible and we shall search for all possible comparisons formed
by the drugs of interest.
We will not apply any language or date restrictions.
Data collection and analysis
Selection of studies
Two review authors will retrieve and independently assess for in-
clusion all the potential studies we identify. We will resolve any
disagreement through discussion or, if required, in consultation
with a third person.
We will create a Study flow diagram to map out the number of
records identified, included and excluded.
Data extraction and management
We will design a form to extract data. For eligible studies, two
review authors will extract the data using the agreed form.We will
resolve discrepancies through discussion or, if required, we will
consult a third person. We will enter data into a Microsoft Access
document and Review Manager Software (RevMan 2014) and
check for accuracy. When information is unclear, we will attempt
to contact authors of the original reports to provide further details.
The following data will be extracted.
Outcome data
From each included study we will extract: the number of partici-
pants, the gestational age and the parity of participants, and any
exclusion criteria. We will also extract: the interventions being
compared, and their respective primary and secondary outcomes.
All relevant arm level data will be extracted (e.g. number of events
and number of patients for binary outcomes).
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Data on potential effect modifiers
From each included study we will extract the following study,
intervention and population characteristics that may act as effect
modifiers.
1. mode of delivery (vaginal delivery or caesarean section);
2. prior risk of PPH (as defined by trialists and categorised as
low, high, mixed or not stated);
3. dosage, regimen, and route of drug administration
(sublingual, subcutaneous, intramuscular, rectal, oral,
intravenous bolus and/or infusion); and
4. setting of the study (community or hospital).
Other data
From each included study we will extract the following additional
information.
1. country or countries in which the study was performed;
2. date of publication;
3. type of publication (full text publication, abstract
publication, unpublished data); and
4. trial registration reference.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011). We will resolve
any disagreement by discussion or by involving a third assessor.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the methods as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number); or
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth); or
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess blinding separately for different outcomes or classes of
outcomes.
We will assess the methods as:
• low, high or unclear risk of bias for participants; and
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will assess blinding separately for dif-
ferent outcomes or classes of outcomes.
We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome
or class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We will state whether attrition
and exclusions were reported and the numbers included in the
analysis at each stage (compared with the total randomised par-
ticipants), reasons for attrition or exclusion where reported, and
whether missing data were balanced across groups or were related
to outcomes. Where sufficient information is reported, or can be
supplied by the trial authors, we will re-include missing data in
the analyses which we undertake.
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups and less than 10% of
missing outcome data);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation or more than 10% of missing outcome data); or
• unclear risk of bias.
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(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We will assess the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported); or
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
about other possible sources of bias, such as the source of funding
and potential conflicts of interest.
We will assess these interests as:
• low risk of other bias (public funding or no funding and no
significant conflicts of interest identified);
• high risk of other bias (industry funding or significant
conflicts of interest identified); or
• unclear risk of other bias.
Another source of bias could be generated by the method of mea-
suring blood loss. We will assess the method described in each
study and classify it as at:
• low risk of other bias (objective measurements such as
weighing sponges, measurements in drapes, volumetric
assessment, tagged red cells, etc);
• high risk of other bias (subjective measurement such as
clinical or visual estimates); or
• unclear risk of other bias (unspecified methods of
measurement).
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we will assess
the likely magnitude and direction of the bias and whether we
consider it is likely to impact on the findings. We will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis for information about how the risk of bias
will be incorporated in the sensitivity analysis.
Measures of treatment effect
Relative treatment effects
Wewill summarise relative treatment effects for dichotomous out-
comes as the posterior median odds ratio (MOR) and 95% credi-
ble intervals (CrIs). For continuous scales of measurement we will
use the posterior mean difference (MD), or the standardised mean
difference (SMD)with 95%CrIs if different scales have been used.
Where the target parameter is the effect of treatment on the change
in a continuous measure, such as the change in haemoglobin be-
tween baseline and postpartum we will, where possible, account
for the within-patient correlation between baseline and postpar-
tum estimates (Dias 2013).
Relative treatment ranking
We will also estimate the ranking probabilities for all treatments
of being at each possible rank for each intervention (conditional
on the model and specified vague priors). Then, we will obtain a
treatment hierarchy using the surface under the cumulative rank-
ing curve (SUCRA). SUCRA can also be expressed as a percent-
age interpreted as the percentage of effectiveness or side-effects of
a treatment that would be ranked first without uncertainty. For
primary outcomes, we will assess the robustness of these findings
in sensitivity analysis by considering estimates of mean rank with
95% CrIs.
Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually-randomised trials. We will adjust their standard er-
rors using the methods described in theHandbook [Section 16.3.4
or 16.3.6] using an estimate of the intracluster correlation co-ef-
ficient (ICC) derived from the trial (if possible), from a similar
trial or from a study of a similar population. If we use ICCs from
other sources, we will report this and conduct sensitivity analyses
to investigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit
is considered to be unlikely. However, we will perform sensitivity
analysis to assess the validity of this assumption for primary out-
comes.
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Cross-over trials
This type of trial is not appropriate for this intervention.
Multi-arm trials
Multi-arm trials will be included and we will account for the cor-
relation between the effect sizes in the network meta-analysis. We
will treat multi-arm studies as multiple independent comparisons
in pairwise meta-analyses.
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
in the overall assessment of treatment effect by using sensitivity
analysis. For all outcomes, we will carry out analyses, as far as
possible, on an intention-to-treat basis, i.e. we will attempt to
include all participants randomised to each group in the analyses,
and all participantswill be analysed in the group towhich theywere
allocated, regardless of whether or not they received the allocated
intervention. The denominator for each outcome in each trial
will be the number randomised minus any participants whose
outcomes are known to be missing.
Assessment of clinical and methodological
heterogeneity within treatment comparisons
To evaluate the presence of clinical heterogeneity, we will generate
descriptive statistics for trial and study population characteristics
across all eligible trials that compare each pair of interventions.
We will assess the presence of clinical heterogeneity within each
pairwise comparison by comparing these characteristics.
Assessment of transitivity across treatment
comparisons
We will assess the assumption of transitivity by comparing the
distribution of potential effect modifiers across the different pair-
wise comparisons. In this context we expect that the transitivity
assumption will hold assuming the following.
1. The common treatment used to compare different uterotonics
indirectly is similarwhen it appears in different trials (e.g., oxytocin
is administered in a similar way in oxytocin versus misoprostol
trials and in oxytocin versus oxytocin plus ergometrine trials).
2. All pairwise comparisons do not differ with respect to the dis-
tribution of effect modifiers (e.g., the design and study character-
istics of oxytocin versus misoprostol trials are similar to oxytocin
versus oxytocin plus ergometrine trials).
The assumption of transitivity will be evaluated epidemiologically
by comparing the clinical and methodological characteristics of
sets of studies grouped by treatment comparisons.
Assessment of reporting biases
We will assess potential reporting bias for the primary outcomes
by assessing the sensitivity of results to exclusion of studies with
fewer than 400 participants.
Data synthesis
Methods for direct treatment comparisons
Initially, we will perform standard pairwise meta-analyses using a
random-effects model in WinBUGS for every treatment compar-
ison with at least two studies. Review Manager Software (RevMan
2014) will be used to compute the I2 statistic.
Methods for indirect and mixed comparisons
Wewill perform a networkmeta-analysis within a Bayesian frame-
work using WinBUGS 1.4.3 (Lunn 2000). Our a priori belief is
that a random-effectsmodel ismore appropriate because we expect
a degree of clinical heterogeneity between trials. The random-ef-
fects summary will be treated as the average of the range of possible
treatment effects and we will discuss the clinical implications of
treatment effects differing between trials. If the average treatment
effect is not clinically meaningful, we will not combine trials.
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity
In standard pairwise meta-analyses we will estimate different het-
erogeneity variances for each pairwise comparison. In network
meta-analysis we will assume a common estimate for the hetero-
geneity variance across the different comparisons. Non-informa-
tive priors will be used as described in the NICE technical support
document 2 (Dias 2014).
Measures and tests for heterogeneity
We will assess statistically the presence of heterogeneity within
each pairwise comparison for the primary outcomes using the I2
statistic and its 95% CI that measures the percentage of variability
that cannot be attributed to random error.
The assessment of statistical heterogeneity in the entire network
will be based on the magnitude of the heterogeneity variance pa-
rameter (τ 2) estimated from the network meta-analysis models.
For dichotomous outcomes the magnitude of the heterogeneity
variance will be compared with the empirical distribution as de-
rived by Turner (Turner 2012). For the primary outcomes, we will
also estimate a total I2 value for heterogeneity in the network as
described elsewhere.
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Assessment of statistical inconsistency
The statistical agreement between the various sources of evidence
in a network of interventions (consistency) will be evaluated by
global and local approaches to complement the evaluation of tran-
sitivity.
Local approaches for evaluating inconsistency
To evaluate the presence of inconsistency locally we will use the
node-splitting approach within the Bayesian framework. This
technique allows us to split the information contributing to esti-
mates of a parameter (node), into two distinct components: the
“direct” evidence from direct comparison trials or multi-arm trials
that contain this contrast, and the “indirect” based on all the re-
maining evidence. This process will be applied to all contrasts in
the network. We will use node splitting to also generate intuitive
graphics showing the difference between the “direct”, “indirect”
and the combined information.
Global approaches for evaluating inconsistency
To check the assumption of consistency in the entire network we
will use the ‘Lu & Ades’ (Lu 2006) model. Model comparison
will be based on the Deviance Information Criterion (DIC) statis-
tic, with a difference of five or more being considered meaning-
ful (Spiegelhalter 2002). In addition, the fit of the network meta-
analysis models will be assessed using the posterior mean residual
deviance. If there is a difference of five or more between the num-
ber of data points and the posterior mean residual deviance then a
more detailed investigation will be performed to attempt to iden-
tify the reasons for poor fit. In a well-fitting model, the posterior
mean deviance should be approximately the same as the number
of unconstrained data points (Dempster 1997). Due to the way
the residual deviance is calculated, if there are zero events in one
of the arms of a trial there may be computational difficulties and
the residual deviance may be artificially inflated. Therefore, for the
purposes of assessing model fit, the contribution of these trials to
the residual deviance and the number of independent data points,
will not be included. We will also provide plots of the individual
contributions to the deviance of each data point for the network
meta-analysis compared to the ’Lu & Ades’ model. If inconsis-
tency cannot be explained or modelled, then the network meta-
analysis will not be performed for that outcome.
Investigation of heterogeneity and inconsistency
If we find important heterogeneity and/or inconsistency, we will
explore the possible sources for both primary and secondary out-
comes. If sufficient studies are available, we will perform meta-
regression or subgroup analyses by using the following potential
effect modifiers as possible sources of inconsistency and/or hetero-
geneity.
• Mistakes and inconsistencies in data extraction and entry.
• Population: prior risk of PPH (high versus low), mode of
delivery (vaginal delivery versus caesarean section), setting
(hospital versus community).
• Intervention: dose, regimen or route.
• Quality of the studies: studies will be ranked as “low risk of
bias” if they are double-blinded, and have allocation concealment
with little loss to follow-up (less than 10%). The concealed
studies with assessor blinding and little loss to follow-up (less
than 10%) will be ranked as “intermediate risk of bias” and the
rest as “high risk of bias”. We consider that assessor blinding is
likely to be very important, in order to eliminate any risk of bias
in subjective measurements or estimates of blood loss (not all
studies measure this outcome objectively). We consider protocol
publication in advance of the results to be an unsuitable criterion
for sensitivity analyses, because protocol publication only
became widespread in recent years.
• Funding source (high versus low risk of bias).
• Whether an objective method of outcome assessment was
employed (objective versus subjective). Objective methods of
blood loss measurement are considered to be all methods that
employ a measurement of the blood loss. This is in contrast to
subjective methods where a healthcare professional is estimating
the blood loss, usually visually.
• Trial size (excluding small studies, in recognition of the
greater likelihood for small studies than large or multi-centre
studies to suffer publication bias). In terms of trial size, there is
evidence that smaller studies can exaggerate estimated benefits
(Nüesch 2010). However, the cut-off for deciding the definition
of a small study can vary between research topics. For this topic,
it appears that trials with more than 400 participants are more
likely to be of higher quality, prospectively registered and overall
at low risk of bias.
• Randomisation unit (cluster versus individual).
Subgroup analysis
For the primary outcomeswewill carry out the following subgroup
analyses.
• Population: prior risk of PPH (high versus low), mode of
delivery (vaginal delivery versus caesarean section), setting
(hospital versus community).
• Intervention: dose, regimen or route.
Wewill assess subgroupdifferences by evaluating the relative effects
and assessment of model fit.
Sensitivity analysis
For the primary outcomes we will perform sensitivity analysis for
the following.
• Quality of the studies as described previously.
• Funding source as described previously.
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• Whether an objective method of outcome assessment was
employed (objective versus subjective).
• Trial size as described previously.
• Randomisation unit (cluster versus individual).
• Choice of relative effect measure (risk ratio versus odds
ratio).
• Use of fixed-effect versus random-effects model.
• Choice of prior distribution.
Differences will be assessed by evaluating the relative effects and
assessment of model fit.
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A P P E N D I C E S
Appendix 1. Search terms
ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP)
Third stage AND labo(u)r AND oxytocin
Third stage AND labo(u)r AND misoprostol
Third stage AND labo(u)r AND carbetocin







h(a)emorrhage AND postpartum AND ergometrine
h(a)emorrhage AND postpartum AND oxytocin
h(a)emorrhage AND postpartum AND carbetocin
h(a)emorrhage AND postpartum AND misoprostol
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